Over the past few years, peptides have quietly moved from the fringes of longevity medicine into the mainstream of reproductive research. And for good reason. As we unravel the cellular forces driving fertility—oxidative stress, mitochondrial fatigue, inflammation, and age-related signaling changes—we are discovering that specific peptides may hold real promise in supporting both male and female reproductive health.
While we’re not yet at the point of routine clinical use, the science is evolving quickly. And for anyone trying to conceive—or planning ahead—these emerging findings are worth understanding.
Peptides are short strings of amino acids—think of them as small biological “messengers” that help regulate countless physiological processes. Some stimulate hormone release. Others support mitochondrial energy. Some fine-tune inflammation or help tissues repair.
Many are naturally produced by your body; others are bioidentical versions that have been studied in clinical trials. Their appeal lies in their precision: they can target specific pathways without the side effects of broader medications.
Kisspeptin is one of the most exciting peptides in reproductive medicine. Often referred to as the “gatekeeper of puberty,” it plays a central role in triggering GnRH release, which controls the entire reproductive hormone cascade.
Recent clinical trials have shown that kisspeptin-54 can safely trigger egg maturation during IVF—offering an alternative to hCG with a lower risk of ovarian hyperstimulation syndrome (OHSS).¹ This could be a game-changer for high-risk patients and those with elevated AMH or PCOS.
Researchers are also exploring kisspeptin’s potential role in boosting sperm function, improving implantation, and even modulating mood and sexual desire—all interconnected pieces of fertility.
Mitochondria matter. They are the energy engines of eggs and sperm, and they age just like we do. MOTS-c is a mitochondrial-derived peptide (MDP) that helps regulate metabolism, oxidative stress, and cellular resilience.
New animal studies show that MOTS-c can improve ovarian reserve markers, enhance oocyte quality, and counteract metabolic dysfunction related to aging and obesity.² While early, this line of research aligns perfectly with what we already know: healthy mitochondria are essential for healthy embryos.
For women over 35—and men facing age-related declines—MDPs may someday become part of a personalized approach to reproductive longevity.
In January 2025, a Science paper shook the field by demonstrating that muscle-derived myostatin is a primary endocrine driver of FSH synthesis.³ This discovery reframes how we understand the muscle–pituitary–ovary axis.
If manipulated safely in the future, myostatin-targeting peptides could help regulate FSH levels more precisely, with potential applications in patients with low ovarian reserve or for optimizing ovarian stimulation protocols. We are only at the beginning, but this pathway opens an entirely new chapter in fertility science.
BPC-157 is widely discussed in regenerative medicine for its potential tissue-healing properties. Although fertility-specific studies are limited, preliminary evidence suggests it may support angiogenesis and reduce inflammatory stress—two key factors in endometrial receptivity.⁴
Right now, the evidence is early and not ready for routine use in fertility care, but it’s a space worth watching.
Growth hormone (GH) plays a known role in ovarian function, follicular development, and endometrial health. GH-releasing peptides (such as GHRP-2 or CJC-1295) are being explored in the longevity field, but data on fertility remain mixed.
Some studies suggest GH can improve outcomes for women with poor ovarian response,⁵. Still, the evidence is not yet strong enough to support widespread use of synthetic GH-releasing peptides in natural fertility.
As always, the message is balance: promising pathways, but not ready for mainstream clinical practice.
Peptides represent one of the most intriguing scientific frontiers in reproductive medicine. The future may bring:
- Personalized peptide protocols for egg and sperm quality
- New ovulation-triggering methods with lower risk
- Targeted mitochondrial support
- Improved implantation environments
- Novel approaches to age-related fertility decline
But we need more human data, safety trials, and long-term follow-up.
As I often remind my patients and readers, we can be excited, but we must also be careful. The best fertility outcomes still come from foundational work—nutrition, sleep, stress, reduction of environmental toxins, microbiome support, and optimizing metabolic health.
Peptides may eventually add to this toolkit, and I’ll be watching the science closely.
Dr Marina OBGYN